Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 10;13(7):1117.
doi: 10.3390/jpm13071117.

Surgical Site Infections in Glioblastoma Patients-A Retrospective Analysis

Affiliations

Surgical Site Infections in Glioblastoma Patients-A Retrospective Analysis

Maximilian Scheer et al. J Pers Med. .

Abstract

Surgical site infections (SSIs) after craniotomy lead to additional morbidity and mortality for patients, which are related to higher costs for the healthcare system. Furthermore, SSIs are associated with a longer hospital stay for the patient, which is particularly detrimental in glioblastoma patients due to their limited life expectancy. Risk factors for SSIs have already been described for craniotomies in general. However, there is limited data available for glioblastoma patients. As postoperative radiation influences wound healing, very early radiation is suspected to be a risk factor for SSI. Nevertheless, there are no data on the optimal timing of radiotherapy. To define risk factors for these patients, we analyzed our collective. We performed a retrospective analysis of all operations with histological evidence of a glioblastoma between 2012 and 2021. Open biopsy and tumor removal (gross total resection, subtotal resection) were included. Stereotactic biopsies were excluded. Demographic data such as age and gender, as well as duration of surgery, diameter of the trepanation, postoperative radiation with interval, postoperative chemotherapy, highest blood glucose level, previous surgery, ASA score, foreign material introduced, subgaleal suction drainage, ventricle opening and length of hospital stay, were recorded. The need for surgical revision due to infection was registered as an SSI. A total of 177 patients were included, of which 14 patients (7.9%) suffered an SSI. These occurred after a median of 45 days. The group with SSIs tended to include more men (57.1%, p = 0.163) and more pre-operated patients (50%, p = 0.125). In addition, foreign material and subgaleal suction drains had been implanted more frequently and the ventricles had been opened more frequently, without reaching statistical significance. Surprisingly, significantly more patients without SSIs had been irradiated (80.3%, p = 0.03). The results enable a better risk assessment of SSIs in glioblastoma patients. Patients with previous surgery, introduced foreign material, subgaleal suction drain and opening of the ventricle may have a slightly higher for SSIs. However, because none of these factors were significant, we should not call them risk factors. A less radical approach to surgery potentially involving these factors is not justified. The postulated negative role of irradiation was not confirmed, hence a rapid chemoradiation should be induced to achieve the best possible oncologic outcome.

Keywords: glioblastoma; influencing factor; irradiation; radicality; retrospective analysis; surgical site infection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart on the progress of the study and the data analysis (created with BioRender®, Toronto, Canada).
Figure 2
Figure 2
Factors with the greatest influence on SSIs measured using odds ratio (OR) (created with BioRender®).
Figure 3
Figure 3
Possible influence of the radicality of the surgery with regard to oncological outcome and SSIs (created with Biorender®, Toronto, Canada).

References

    1. Fang C., Zhu T., Zhang P., Xia L., Sun C. Risk factors of neurosurgical site infection after craniotomy: A systematic review and meta-analysis. Am. J. Infect. Control. 2017;45:e123–e134. doi: 10.1016/j.ajic.2017.06.009. - DOI - PubMed
    1. Delgado-López P.D., Corrales-García E.M. Survival in glioblastoma: A review on the impact of treatment modalities. Clin. Transl. Oncol. 2016;18:1062–1071. doi: 10.1007/s12094-016-1497-x. - DOI - PubMed
    1. Wirsching H.-G., Galanis E., Weller M. Glioblastoma. [(accessed on 1 July 2023)];Handb. Clin. Neurol. 2016 134:381–397. Available online: https://pubmed.ncbi.nlm.nih.gov/26948367/ - PubMed
    1. Perry J.R., Laperriere N., O’Callaghan C.J., Brandes A.A., Menten J., Phillips C., Fay M., Nishikawa R., Cairncross G., Roa W., et al. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N. Engl. J. Med. 2017;376:1027–1037. doi: 10.1056/NEJMoa1611977. - DOI - PubMed
    1. Stupp R., Taillibert S., Kanner A., Read W., Steinberg D., Lhermitte B., Toms S., Idbaih A., Ahluwalia M.S., Fink K., et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318:2306–2316. doi: 10.1001/jama.2017.18718. - DOI - PMC - PubMed